StockData

NewAmsterdam Pharma vs Zentalis Pharmaceuticals

NAMS and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNAMSZNTL
Size and price
Market cap–$107M
Share price$19.39$1.49
Change, 1 year−49.4%12.0%
Change, 5 years98.1%−98.0%
Beta (5Y)1.575.80
Employees100106
StockData Score
Total score66
Valuation score01 (better)
Growth score00
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/B–0.7×
FCF yield–−120%
Growth
Revenue growth (TTM)−88.9%–
Profitability
Operating margin−3432%–
Net margin−3644%–
FCF margin−2018%–
Return on equity−36.8% (better)−66.7%
Return on invested capital−1046%–
Financial health
Debt / equity0.000.00
Current ratio9.03 (better)4.82
Altman Z-score–−8.91
Piotroski F-score3 (better)1
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–66.1%
Held by insiders22.0%58.0%
Insider net buying, 12 months−$63.0M$12.8M (better)
Short interest, % of float–16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.